255 related articles for article (PubMed ID: 10354404)
1. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
2. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
3. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.
Zhang X; Boyar W; Galakatos N; Gonnella NC
Protein Sci; 1997 Jan; 6(1):65-72. PubMed ID: 9007977
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of antagonists of the C5a receptor.
Paczkowski NJ; Finch AM; Whitmore JB; Short AJ; Wong AK; Monk PN; Cain SA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Dec; 128(7):1461-6. PubMed ID: 10602324
[TBL] [Abstract][Full Text] [Related]
7. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
[TBL] [Abstract][Full Text] [Related]
8. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
9. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats.
Strachan AJ; Woodruff TM; Haaima G; Fairlie DP; Taylor SM
J Immunol; 2000 Jun; 164(12):6560-5. PubMed ID: 10843715
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine.
Arumugam TV; Shiels IA; Woodruff TM; Reid RC; Fairlie DP; Taylor SM
J Surg Res; 2002 Apr; 103(2):260-7. PubMed ID: 11922743
[TBL] [Abstract][Full Text] [Related]
11. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
Woodruff TM; Strachan AJ; Dryburgh N; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Arthritis Rheum; 2002 Sep; 46(9):2476-85. PubMed ID: 12355496
[TBL] [Abstract][Full Text] [Related]
12. Synthetic small-molecule complement inhibitors.
Holland MC; Morikis D; Lambris JD
Curr Opin Investig Drugs; 2004 Nov; 5(11):1164-73. PubMed ID: 15573867
[TBL] [Abstract][Full Text] [Related]
13. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
14. Expression of an epitope tagged human C5a receptor and antibody-mediated immobilization of detergent-solubilized receptor for drug discovery screening.
Sloan DD; Barrett RW; Tate EH; England BP
Protein Expr Purif; 1997 Oct; 11(1):119-24. PubMed ID: 9325147
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist.
Haynes DR; Harkin DG; Bignold LP; Hutchens MJ; Taylor SM; Fairlie DP
Biochem Pharmacol; 2000 Sep; 60(5):729-33. PubMed ID: 10927032
[TBL] [Abstract][Full Text] [Related]
16. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.
Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM
Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.
Short A; Wong AK; Finch AM; Haaima G; Shiels IA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Feb; 126(3):551-4. PubMed ID: 10188960
[TBL] [Abstract][Full Text] [Related]
18. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides.
Baranyi L; Campbell W; Okada H
J Immunol; 1996 Nov; 157(10):4591-601. PubMed ID: 8906838
[TBL] [Abstract][Full Text] [Related]
19. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease.
Woodruff TM; Pollitt S; Proctor LM; Stocks SZ; Manthey HD; Williams HM; Mahadevan IB; Shiels IA; Taylor SM
J Pharmacol Exp Ther; 2005 Aug; 314(2):811-7. PubMed ID: 15879003
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin.
Ni F; Carpenter KA; Ripoll DR; Sanderson SD; Hugli TE
Biopolymers; 1996 Jan; 38(1):31-41. PubMed ID: 8679942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
